Trapezius myofascial pain: shockwaves versus low-level laser · Randomized trial · 2018
How does shockwave compare with laser for trapezius muscle pain?
In this trial, resting pain fell by about 20 points on a 0–100 scale with three weekly shockwave sessions and with 15 laser sessions, and the groups ended close at 15 weeks. Pressure pain on the left side fell more with shockwave.
No clear difference between the groups- adults with trapezius muscle pain
- 61
- shockwave sessions, one a week
- 3
- weeks of follow-up
- 15
Good to know: Laser took 15 sessions; shockwave took 3.
Király M, Bender T, Hodosi K Rheumatol Int, 2018 · Read the paper ↗
How this study worked
What happened
Neck and shoulder pain at rest
0–100 pain scale · start, end of treatment and week 15
ShockwaveLow-level laser
Show the numbers
| Group | Start | Week 3 | Week 15 |
|---|---|---|---|
| Shockwave | 47.7 | 25.7 | 25.4 |
| Low-level laser | 46.06 | 25.16 | 22.42 |
The treatment
Shockwave
Shockwave, once a week for 3 weeks
- Sessions
- 3, one a week
- Pulses
- 1,000 per area · twice: around the trigger point, then on it
- Strength
- 1.5–2bar 0.25 mJ/mm² printed for both steps · 10 per second
- Numbing
- Not mentioned
- Device
- BTL-6000 SWT Topline Power
- Everyone also got
- No other physiotherapy during follow-up
Compared with: Low-level laser on 15 working days over three weeks
Settings are what each study used, not a prescription.
Who took part
61 adults, mostly women in their late 50s and early 60s, with trapezius muscle pain for at least 8 weeks, at a Hungarian hospital clinic.
Side effects
The authors say there were no side effects.
All the numbers and the full appraisal
The results, in numbers.
Adults from a Hungarian county teaching hospital rheumatology outpatient clinic (February 2016–September 2017) with trapezius myofascial pain by Simons criteria and neck/shoulder pain for at least 8 weeks. Laser group: 31 (27 women, mean age 62.62); shockwave group: 30 (27 women, mean age 57.26).
31 randomized and treated; 1 lost to follow-up for non-compliance; all 31 analysed with last observation carried forward.
30 randomized and treated; none lost; 30 analysed.
Pain at rest2 reported outcomes
Pain at rest
100 mm visual analogue scale (VAS), rest pain mm on a 100 mm VAS
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 46.06 (SD 18.02) | 25.16 (SD 18.63) |
| Shockwaves | 30 | 47.7 (SD 20.75) | 25.7 (SD 25.56) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Resting pain fell by about 20 mm in both groups. The between-group differences were small with wide intervals crossing zero at week 3 (1.030; P=0.822) and week 15 (−1.345; P=0.840). The abstract calls the week-15 value a significant laser advantage and the Results text calls week 3 a significant shockwave advantage; Table 1 supports neither.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
Pain at rest
100 mm visual analogue scale (VAS), rest pain mm on a 100 mm VAS
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 46.06 (SD 18.02) | 22.42 (SD 21.39) |
| Shockwaves | 30 | 47.7 (SD 20.75) | 25.4 (SD 22.67) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Resting pain fell by about 20 mm in both groups. The between-group differences were small with wide intervals crossing zero at week 3 (1.030; P=0.822) and week 15 (−1.345; P=0.840). The abstract calls the week-15 value a significant laser advantage and the Results text calls week 3 a significant shockwave advantage; Table 1 supports neither.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
Pressure pain, left trapezius4 reported outcomes
Pressure pain, left trapezius
100 mm VAS at a standardized dolorimeter pressure (BASELINE) mm on a 100 mm VAS
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 100 | 61.65 (SD 24.7) |
| Shockwaves | 30 | 100 | 46.73 (SD 23.14) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Left trapezius: pain under the standardized pressure fell more with shockwaves, by 14.911 mm at week 3 (95% CI 2.641 to 27.182; P=0.018) and 17.190 mm at week 15 (4.326 to 30.055; P=0.010). The right side did not show this, which the authors attribute to chance or the small sample.
Analysis details and source
By design, baseline pressure was set where each patient reported maximal pain, so baseline VAS is 100 in both groups (no SD); later visits repeat the same pressure. Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
Pressure pain, left trapezius
100 mm VAS at a standardized dolorimeter pressure (BASELINE) mm on a 100 mm VAS
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 100 | 59.29 (SD 21.65) |
| Shockwaves | 30 | 100 | 42.1 (SD 28.23) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Left trapezius: pain under the standardized pressure fell more with shockwaves, by 14.911 mm at week 3 (95% CI 2.641 to 27.182; P=0.018) and 17.190 mm at week 15 (4.326 to 30.055; P=0.010). The right side did not show this, which the authors attribute to chance or the small sample.
Analysis details and source
By design, baseline pressure was set where each patient reported maximal pain, so baseline VAS is 100 in both groups (no SD); later visits repeat the same pressure. Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
Pressure pain, right trapezius
100 mm VAS at a standardized dolorimeter pressure (BASELINE) mm on a 100 mm VAS
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 100 | 60.65 (SD 21.6) |
| Shockwaves | 30 | 100 | 56.57 (SD 22.17) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Right trapezius: pain under the standardized pressure fell in both groups; the between-group differences (4.078 at week 3, 9.561 at week 15) had intervals crossing zero (P=0.470 and 0.135).
Analysis details and source
By design, baseline pressure was set where each patient reported maximal pain, so baseline VAS is 100 in both groups (no SD); later visits repeat the same pressure. Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
Pressure pain, right trapezius
100 mm VAS at a standardized dolorimeter pressure (BASELINE) mm on a 100 mm VAS
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 100 | 56.16 (SD 21.17) |
| Shockwaves | 30 | 100 | 46.6 (SD 27.74) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Right trapezius: pain under the standardized pressure fell in both groups; the between-group differences (4.078 at week 3, 9.561 at week 15) had intervals crossing zero (P=0.470 and 0.135).
Analysis details and source
By design, baseline pressure was set where each patient reported maximal pain, so baseline VAS is 100 in both groups (no SD); later visits repeat the same pressure. Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
Neck disability2 reported outcomes
Neck disability
Neck Disability Index (NDI) points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 15.55 (SD 6.09) | 10.51 (SD 7.28) |
| Shockwaves | 30 | 16.08 (SD 7.58) | 10.38 (SD 6.9) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
NDI improved by about 5–7 points in both groups. Between-group differences were 0.660 at week 3 (95% CI −1.933 to 3.253; P=0.612) and 1.072 at week 15 (−2.110 to 4.254; P=0.503). The abstract and Results text describe a significantly larger shockwave improvement, which these intervals do not show.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
Neck disability
Neck Disability Index (NDI) points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 15.55 (SD 6.09) | 10.01 (SD 6.91) |
| Shockwaves | 30 | 16.08 (SD 7.58) | 9.47 (SD 5.65) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
NDI improved by about 5–7 points in both groups. Between-group differences were 0.660 at week 3 (95% CI −1.933 to 3.253; P=0.612) and 1.072 at week 15 (−2.110 to 4.254; P=0.503). The abstract and Results text describe a significantly larger shockwave improvement, which these intervals do not show.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Physical functioning2 reported outcomes
SF-36 Physical functioning
SF-36, physical functioning domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 62.26 (SD 16.47) | 69.03 (SD 18.86) |
| Shockwaves | 30 | 67.83 (SD 20.12) | 76.67 (SD 18.3) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Physical functioning
SF-36, physical functioning domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 62.26 (SD 16.47) | 69.84 (SD 18.46) |
| Shockwaves | 30 | 67.83 (SD 20.12) | 77.89 (SD 19.19) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Role limitation, physical2 reported outcomes
SF-36 Role limitation, physical
SF-36, role limitation, physical domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 45.16 (SD 36.18) | 59.68 (SD 41.67) |
| Shockwaves | 30 | 40 (SD 35.72) | 68.33 (SD 37.68) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Role limitation, physical
SF-36, role limitation, physical domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 45.16 (SD 36.18) | 56.45 (SD 41.32) |
| Shockwaves | 30 | 40 (SD 35.72) | 70.83 (SD 37.18) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Role limitation, emotional2 reported outcomes
SF-36 Role limitation, emotional
SF-36, role limitation, emotional domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 62.35 (SD 40.18) | 63.43 (SD 39.76) |
| Shockwaves | 30 | 59.99 (SD 41.43) | 73.32 (SD 36.52) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Role limitation, emotional
SF-36, role limitation, emotional domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 62.35 (SD 40.18) | 62.35 (SD 43.67) |
| Shockwaves | 30 | 59.99 (SD 41.43) | 77.77 (SD 37.48) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Energy/fatigue2 reported outcomes
SF-36 Energy/fatigue
SF-36, energy/fatigue domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 60.19 (SD 18.95) | 66.29 (SD 16.53) |
| Shockwaves | 30 | 53.17 (SD 19) | 66.5 (SD 16.3) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Energy/fatigue
SF-36, energy/fatigue domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 60.19 (SD 18.95) | 68.87 (SD 17.5) |
| Shockwaves | 30 | 53.17 (SD 19) | 69.67 (SD 13.89) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Emotional well-being2 reported outcomes
SF-36 Emotional well-being
SF-36, emotional well-being domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 72.9 (SD 19.18) | 74.84 (SD 19.38) |
| Shockwaves | 30 | 69.2 (SD 16.94) | 79.8 (SD 14.6) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Emotional well-being
SF-36, emotional well-being domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 72.9 (SD 19.18) | 74.84 (SD 20.11) |
| Shockwaves | 30 | 69.2 (SD 16.94) | 77.47 (SD 14.72) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Social functioning2 reported outcomes
SF-36 Social functioning
SF-36, social functioning domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 73.39 (SD 20.61) | 81.05 (SD 17.93) |
| Shockwaves | 30 | 72.5 (SD 17.8) | 82.5 (SD 17.25) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Social functioning
SF-36, social functioning domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 73.39 (SD 20.61) | 79.44 (SD 20.04) |
| Shockwaves | 30 | 72.5 (SD 17.8) | 84.17 (SD 19.4) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Bodily pain2 reported outcomes
SF-36 Bodily pain
SF-36, bodily pain domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 50.64 (SD 15.07) | 62.82 (SD 19.93) |
| Shockwaves | 30 | 44.5 (SD 20.12) | 63.17 (SD 17.26) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 Bodily pain
SF-36, bodily pain domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 50.64 (SD 15.07) | 69.11 (SD 17.94) |
| Shockwaves | 30 | 44.5 (SD 20.12) | 69.08 (SD 18.53) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 General health2 reported outcomes
SF-36 General health
SF-36, general health domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 51.94 (SD 15.37) | 55.97 (SD 17.82) |
| Shockwaves | 30 | 52.23 (SD 20.83) | 57.33 (SD 20.96) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 3
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
SF-36 General health
SF-36, general health domain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Low-level laser | 31 | 51.94 (SD 15.37) | 56.29 (SD 17.84) |
| Shockwaves | 30 | 52.23 (SD 20.83) | 57.46 (SD 19.1) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Laser versus shockwaves, change from week 0 to week 15
Unadjusted
Of the 16 SF-36 between-group contrasts in Table 1, only two have P<0.05: role limitation (physical) at week 15 (−19.543; P=0.037) and emotional well-being at week 3 (−8.665; P=0.012), and in both the printed 95% CI includes zero, which contradicts the P value. The other 14 intervals cross zero. The abstract claim of significantly better change "in all domains" is not supported by the table.
Analysis details and source
Mean ± SD and between-group difference in change from baseline (95% CI) as printed. Analysis sets were 31 laser and 30 shockwave participants, with the one laser dropout imputed by last observation carried forward. Table 1 does not define the sign of the between-group difference; the printed values are consistent with laser-group change minus shockwave-group change, so for pain and NDI a positive value favours shockwaves and for SF-36 a negative value favours shockwaves.
Patient-signed medication record1 reported outcome
Took pain or muscle medication
Patient-signed medication record participants
Laser versus shockwaves, proportion taking medication at week 15
Chi-square or Fisher exact test
Medication use was uncommon in both groups at every visit (week 3: 4/31 laser vs 7/30 shockwaves, P=0.389; week 15: 8/31 vs 5/30, P=0.384). Medication for more than a week: 0/31 laser vs 4/30 shockwaves at week 3 and 1/31 vs 3/30 at week 15 (P=0.354); the text says most medicated patients took it for under a week, which holds for the laser arm but not the shockwave arm.
Analysis details and source
Counts as printed in Table 3; the Medicine <1 week / >1 week rows have missing percentages for some cells.
Clinical palpation1 reported outcome
Palpable muscle knot (myogelosis) present
Clinical palpation participants
Laser versus shockwaves, proportion with myogelosis at week 15
Chi-square or Fisher exact test
Knots were present at baseline in 12/30 laser and 15/26 shockwave participants and at week 15 in 6/30 and 7/26 (P=0.587).
Analysis details and source
Table 3 uses denominators of 30 and 26 for this row, unlike the 31 and 30 analysed elsewhere; the paper does not explain the difference.
Patient impression of change1 reported outcome
Patient impression of change
Qualitative finding
On a 4-grade Likert scale (1 significantly improved to 4 worsened), the text reports that 86.6% improved and 13.3% were unchanged in both groups after therapy and at week 15. Table 2 prints means of 2.00±0.52 and 1.73±0.69 (laser) and 1.73±0.69 and 1.90±0.61 (shockwaves) with between-group P values of 0.078 and 0.283.
Analysis details and source
Table 2 column headings (outcome measure 0, 1, 2) do not align clearly with these values, since impression was not rated at week 0; the visit for each mean is therefore uncertain and no numeric groups are charted.
How treatment was delivered
BTL-6000 SWT Topline Power; the Introduction describes energy produced by high-pressure air. The paper does not label it radial or focused.
1,000 impulses around the trigger point at 1.5 bar and 10 Hz, then 1,000 on the trigger point at 2 bar and 10 Hz, 15 mm head; energy density printed as 0.25 mJ/mm² for both steps.
Once weekly for 3 weeks (3 sessions). Completion required at least 80% of sessions. Anesthesia not mentioned.
Low-level laser (PR999 4 W scanning laser, Medical Italia) on 15 working days over 3 weeks: 2 minutes around the trigger point at 2000 Hz (800 mW), 3 J/cm², and 2 minutes on the trigger point at 5000 Hz (2000 mW), 9 J/cm². No other physiotherapy during follow-up; rescue medication was recorded.
Computer-generated allocation by an independent technician, sealed opaque envelopes; testing investigator and statistician blinded; patients not blinded.
The authors state that no adverse events were noted or recorded and that patients reported no side effects. How adverse events were sought is not described; Table 3 cited for this statement reports medication use and myogelosis only.
Author-reported: large SDs and non-homogeneous baseline values; subjective patient-completed measures; wide age range; small sample; follow-up of only 15 weeks; an 8-week minimum symptom duration that may be short.
Abstract and text versus table: the abstract reports significantly better neck function with shockwaves (CIs −1.933 to 3.253 and −2.110 to 4.254), significantly better change in all SF-36 domains, and a significant laser advantage in resting pain at week 15 (P=0.840); the Results text adds a significant shockwave advantage for resting pain at week 3 (P=0.822). Table 1 supports none of these statements.
Within Table 1, role limitation (physical) at week 15 (P=0.037; CI −37.894 to 1.192) and emotional well-being at week 3 (P=0.012; CI −15.375 to 1.954) pair a significant P value with an interval that includes zero; a sign may be missing from the upper limit, but the paper does not say. The direction of the between-group difference is not defined.
Statistical methods state both that missing data were imputed by last observation carried forward and that no intention-to-treat analysis was used; Figure 1 analyses all 31 laser patients despite one loss to follow-up. Mann–Whitney/t tests on change scores were used; no primary outcome or multiplicity correction is named in the article.
Registry check by the extractor: ClinicalTrials.gov NCT03436459 was first submitted on 11 February 2018, after the study ended in September 2017; it lists eight primary outcomes (rest pain, pressure pain, function and quality of life at weeks 3 and 15) and actual enrolment of 60, whereas the article reports 61 randomized.
Extractor: the arms differed in contact time (15 laser visits versus 3 shockwave visits) and mean age (62.62 versus 57.26 years); patients were unblinded to visibly different treatments, and the pain, function, quality-of-life and impression outcomes were patient-rated. Funding: none. Conflicts: none declared.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Author-reported: large SDs and non-homogeneous baseline values; subjective patient-completed measures; wide age range; small sample; follow-up of only 15 weeks; an 8-week minimum symptom duration that may be short.
- Abstract and text versus table: the abstract reports significantly better neck function with shockwaves (CIs −1.933 to 3.253 and −2.110 to 4.254), significantly better change in all SF-36 domains, and a significant laser advantage in resting pain at week 15 (P=0.840); the Results text adds a significant shockwave advantage for resting pain at week 3 (P=0.822). Table 1 supports none of these statements.
- Within Table 1, role limitation (physical) at week 15 (P=0.037; CI −37.894 to 1.192) and emotional well-being at week 3 (P=0.012; CI −15.375 to 1.954) pair a significant P value with an interval that includes zero; a sign may be missing from the upper limit, but the paper does not say. The direction of the between-group difference is not defined.
- Statistical methods state both that missing data were imputed by last observation carried forward and that no intention-to-treat analysis was used; Figure 1 analyses all 31 laser patients despite one loss to follow-up. Mann–Whitney/t tests on change scores were used; no primary outcome or multiplicity correction is named in the article.
- Registry check by the extractor: ClinicalTrials.gov NCT03436459 was first submitted on 11 February 2018, after the study ended in September 2017; it lists eight primary outcomes (rest pain, pressure pain, function and quality of life at weeks 3 and 15) and actual enrolment of 60, whereas the article reports 61 randomized.
- Extractor: the arms differed in contact time (15 laser visits versus 3 shockwave visits) and mean age (62.62 versus 57.26 years); patients were unblinded to visibly different treatments, and the pain, function, quality-of-life and impression outcomes were patient-rated. Funding: none. Conflicts: none declared.
Source-linked critical reading
randomized trial
Technical source record
Complete local PDF read (8 pages), including all body sections, Tables 1–3, Figure 1, funding, conflict statement and references; ClinicalTrials.gov record NCT03436459 checked for dates and outcomes. No supplement is referenced.
In 61 adults with trapezius myofascial pain, three weekly shockwave sessions and 15 laser sessions were followed by improvements of similar average size in resting pain and neck function up to 15 weeks; the between-group intervals were wide (resting pain −14.6 to 11.9 mm at week 15), so the trial cannot show the two work equally well. Pain under pressure on the left side improved more with shockwaves; the broader advantage the authors describe is not borne out by their own table.
In trapezius myofascial pain syndrome, do three weekly shockwave sessions change pain, neck function and quality of life differently from 15 sessions of low-level laser?
Single-centre randomized trial with concealed allocation and a blinded tester and statistician; 61 of 70 screened were randomized (31 laser, 30 shockwaves). Patients were not blinded. Registered as NCT03436459, but only after the study ended.
Adults from a Hungarian county teaching hospital rheumatology outpatient clinic (February 2016–September 2017) with trapezius myofascial pain by Simons criteria and neck/shoulder pain for at least 8 weeks. Laser group: 31 (27 women, mean age 62.62); shockwave group: 30 (27 women, mean age 57.26).
BTL-6000 SWT Topline Power shockwaves (a compressed-air device per the Introduction; the paper does not use the word radial), once weekly for 3 weeks: 1,000 impulses around the trigger point at 1.5 bar, 10 Hz, then 1,000 impulses on the trigger point at 2 bar, 10 Hz, 15 mm head; energy density printed as 0.25 mJ/mm² for both steps.
Low-level laser (PR999 4 W scanning laser, Medical Italia) on 15 working days over 3 weeks: 2 minutes around the trigger point at 2000 Hz (800 mW), 3 J/cm², and 2 minutes on the trigger point at 5000 Hz (2000 mW), 9 J/cm². No other physiotherapy during follow-up; rescue medication was recorded.
Resting pain (100 mm VAS), pain under a standardized dolorimeter pressure on each trapezius, Neck Disability Index, SF-36 domains, medication use, myogelosis and a 4-grade patient impression, at weeks 0, 3 and 15. No single primary outcome is named in the article.
Resting pain, NDI and SF-36 scores improved in both groups. Between groups, resting pain (week 15: −1.345; 95% CI −14.600 to 11.910) and NDI (1.072; −2.110 to 4.254) showed no clear difference; left-trapezius pressure pain fell more with shockwaves (17.190 mm; 4.326 to 30.055) but right-side pressure pain did not. Only 2 of 16 SF-36 contrasts had P<0.05, each with a printed CI that includes zero. The abstract and text describe significant shockwave advantages for neck function and all SF-36 domains, and a significant laser advantage in week-15 resting pain; Table 1 does not show these.
The authors state that no adverse events were noted or recorded and that patients reported no side effects. How adverse events were sought is not described; Table 3 cited for this statement reports medication use and myogelosis only.
Concealed computer randomization with a blinded tester and statistician, but patients were unblinded, outcomes are self-reported, and laser was given 15 times versus shockwaves 3 times. The abstract and text claim significant shockwave advantages in neck function and all SF-36 domains that Table 1 does not show, and two P values conflict with their intervals. Registered retrospectively (ClinicalTrials.gov first submitted February 2018, after completion). No funding; no conflicts declared.
Results concern mainly women (mean ages 57 and 63 years in the two arms) with trapezius myofascial pain in a Hungarian rheumatology clinic, comparing this specific pneumatic shockwave regimen with a 15-session laser regimen. Most between-group contrasts were not statistically significant, with intervals wide enough to include moderate differences in either direction; they do not establish superiority of either treatment or results beyond 15 weeks.
A prospectively registered trial naming one primary outcome, with matched visit schedules or sham control, intention-to-treat analysis, defined effect direction, structured harms recording and longer follow-up.
Read the original article.
Comparative study of shockwave therapy and low-level laser therapy effects in patients with myofascial pain syndrome of the trapezius.
Király M, Bender T, Hodosi K. · Rheumatol Int · 2018
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →